Posted 01 November, 2021
Biofrontera Inc. IPO completed
IPO completed detected for ticker Nasdaq:BFRI in a 424B4 filed on 01 November, 2021.
This is an initial public offering of units, each unit consisting of one share of common stock of Biofrontera Inc. and one warrant to purchase one share of our common stock.
Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of Biofrontera Inc.
Health Care/Life Sciences • Pharmaceuticals
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.Market Cap
$2.27M
View Company Details
$2.27M
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.